News
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...
Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
Verve Therapeutics is at the forefront of gene-editing technology applied to cardiovascular diseases. The company’s lead asset, VERVE-102, targets PCSK9 to reduce LDL cholesterol levels in ...
But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, ...
With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene editing treatments.
💎 Bargain Hunter: Undervalued stocks with massive upside potential Get the list Lilly to acquire Verve Therapeutics for up to $1.3 billion Company News Published 06/17/2025, 06:54 AM 0 ...
Verve Therapeutics is at the forefront of gene-editing technology applied to cardiovascular diseases. The company’s lead asset, VERVE-102, targets PCSK9 to reduce LDL cholesterol levels in patients ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...
Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results